Patents Assigned to Exthera Medical Corporation
-
Patent number: 11911551Abstract: Methods and devices are disclosed for the treatment of a subject suffering from drug intoxication by cleansing a contaminated sample from the subject with adsorption media. The adsorption media composition is selected for its antithrombogenic properties and for its ability to adhere to one or more drug targets to be reduced or eliminated. The media can further be held in a cartridge for use in extracorporeal treatments such as those of hemoperfusion. Contacting the contaminated sample from the subject with the absorption medium allows for the separation of a portion of the drug target from the sample, producing a cleansed sample that can be infused into the subject.Type: GrantFiled: August 28, 2020Date of Patent: February 27, 2024Assignee: ExThera Medical CorporationInventors: Robert S. Ward, Keith R. McCrea
-
Patent number: 11844895Abstract: The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates.Type: GrantFiled: December 19, 2019Date of Patent: December 19, 2023Assignee: ExThera Medical CorporationInventors: Keith McCrea, Robert Ward
-
Patent number: 11306346Abstract: The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.Type: GrantFiled: October 25, 2019Date of Patent: April 19, 2022Assignee: ExThera Medical CorporationInventors: Robert S. Ward, Keith R. McCrea
-
Publication number: 20220072038Abstract: The present invention provides methods and devices for augmenting impaired glycocalyx barrier function in a subject in need thereof by contacting a sample (e.g., blood) obtained from the subject with a glycocalyx-mimetic adsorption media. The adsorption media includes glycosaminoglycan structures and, optionally, proteoglycan core proteins, which are conducive to enhancing and/or restoring the impaired glycocalyx barrier function in a sample. The contacted sample is subsequently separated from the adsorption media, producing a treated sample that can be infused into the subject. Methods and devices for treating a patient suffering from a disease associated with glycocalyx barrier dysfunction are also provided herein.Type: ApplicationFiled: November 15, 2021Publication date: March 10, 2022Applicant: ExThera Medical CorporationInventors: Robert S. Ward, Keith R. McCrea, Lakhmir (Mink) Chawla
-
Patent number: 11266772Abstract: The method is described as the removal of mediators that contribute to the pathogenesis of cancer from blood by contacting the blood with a solid, essentially non-micro-porous substrate which has been surface treated with heparin, heparan sulfate and, optionally, other molecules or chemical groups (the adsorbent media or media) having a binding affinity to the mediator, and wherein the size of the interstitial channels within said substrate are balanced with the amount of interstitial substrate surface area such that high flow rates of blood past said substrate creates a flow transport that is characterized by convection transport more than Brownian diffusion transport.Type: GrantFiled: December 9, 2014Date of Patent: March 8, 2022Assignee: ExThera Medical CorporationInventors: Keith McCrea, Robert Ward, Olle Larm
-
Patent number: 11123466Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.Type: GrantFiled: August 27, 2018Date of Patent: September 21, 2021Assignee: ExThera Medical CorporationInventors: Robert S. Ward, Keith R. McCrea, Olle Larm, Lars Adolfsson
-
Patent number: 11065378Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.Type: GrantFiled: June 4, 2020Date of Patent: July 20, 2021Assignee: ExThera Medical CorporationInventors: Olle Larm, Tomas Bergstrom
-
Publication number: 20210008269Abstract: Methods and devices are disclosed for the treatment of a subject suffering from drug intoxication by cleansing a contaminated sample from the subject with adsorption media. The adsorption media composition is selected for its antithrombogenic properties and for its ability to adhere to one or more drug targets to be reduced or eliminated. The media can further be held in a cartridge for use in extracorporeal treatments such as those of hemoperfusion. Contacting the contaminated sample from the subject with the absorption medium allows for the separation of a portion of the drug target from the sample, producing a cleansed sample that can be infused into the subject.Type: ApplicationFiled: August 28, 2020Publication date: January 14, 2021Applicant: ExThera Medical CorporationInventors: Robert S. WARD, Keith R. McCREA
-
Patent number: 10857283Abstract: The present technology relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, devices are designed to be portable, wearable, disposable and self-contained extracorporeal devices that can be easily assembled from a kit.Type: GrantFiled: September 21, 2015Date of Patent: December 8, 2020Assignee: EXTHERA MEDICAL CORPORATIONInventors: Robert S Ward, Keith R McCrea
-
Publication number: 20200338256Abstract: The present technology relates to methods and devices for the removal of toxins and pathogens from infected blood of patients. In particular, devices are designed to be portable, wearable, disposable and self-contained extracorporeal devices that can be easily assembled from a kit.Type: ApplicationFiled: July 7, 2020Publication date: October 29, 2020Applicant: ExThera Medical CorporationInventors: Robert S. Ward, Keith R. McCrea
-
Patent number: 10786615Abstract: Methods and devices are disclosed for the treatment of a subject suffering from drug intoxication by cleansing a contaminated sample from the subject with adsorption media. The adsorption media composition is selected for its antithrombogenic properties and for its ability to adhere to one or more drug targets to be reduced or eliminated. The media can further be held in a cartridge for use in extracorporeal treatments such as those of hemoperfusion. Contacting the contaminated sample from the subject with the absorption medium allows for the separation of a portion of the drug target from the sample, producing a cleansed sample that can be infused into the subject.Type: GrantFiled: March 1, 2017Date of Patent: September 29, 2020Assignee: EXTHERA MEDICAL CORPORATIONInventors: Robert S. Ward, Keith R. McCrea
-
Publication number: 20200297913Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.Type: ApplicationFiled: June 4, 2020Publication date: September 24, 2020Applicant: ExThera Medical CorporationInventors: Olle Larm, Tomas Bergstrom
-
Patent number: 10688239Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.Type: GrantFiled: January 14, 2019Date of Patent: June 23, 2020Assignee: ExThera Medical CorporationInventors: Olle Larm, Tomas Bergstrom
-
Publication number: 20200171233Abstract: The present invention provides methods for removing a significant amount of bacteria (e.g., gram-negative bacteria and gram-positive bacteria, including bacteria with no or low affinity for heparan sulfate) from whole blood, serum or plasma using an adsorption media. The method can be used in extracorporeal treatments involving high volumetric flow rates and high linear flow rates.Type: ApplicationFiled: December 19, 2019Publication date: June 4, 2020Applicant: ExThera Medical CorporationInventors: Keith McCrea, Robert Ward
-
Patent number: 10639413Abstract: A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin.Type: GrantFiled: August 2, 2018Date of Patent: May 5, 2020Assignee: Exthera Medical CorporationInventors: Keith McCrea, Robert Ward, Olle Larm, Lars Adolfsson
-
Patent number: 10537280Abstract: The present invention is directed to an integrated system and a method for utilizing the system to detect and remove blood-borne factors of interest, such as pathogens and/or toxins and/or cytokines, from blood or serum (blood) by contacting the blood with a solid, essentially nonporous substrate which has been surface treated with molecules or chemical groups (the adsorbent media or media) having a binding affinity for the pathogens and/or toxins to be removed (the adsorbents). The invention can be used to remove virulence factors, e.g. toxins, that are released from various pathogens. In one aspect, the invention is for the treatment of sepsis and infection, such as infections associated with battle field trauma.Type: GrantFiled: August 13, 2013Date of Patent: January 21, 2020Assignee: ExThera Medical CorporationInventors: Keith McCrea, Robert S. Ward, George Pitarra, Jr.
-
Patent number: 10487350Abstract: The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.Type: GrantFiled: October 16, 2015Date of Patent: November 26, 2019Assignee: ExThera Medical CorporationInventors: Robert S. Ward, Keith R. McCrea
-
Patent number: 10457974Abstract: The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.Type: GrantFiled: November 2, 2016Date of Patent: October 29, 2019Assignee: ExThera Medical CorporationInventors: Robert S. Ward, Keith R. McCrea
-
Publication number: 20190143027Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.Type: ApplicationFiled: January 14, 2019Publication date: May 16, 2019Applicant: ExThera Medical CorporationInventors: Olle LARM, Tomas BERGSTROM
-
Publication number: 20190038826Abstract: A blood filtration method, system, device and media for removing gram negative bacteria from the blood wherein the media includes a substrate coated with mannose optionally in constitution with substrate coated with heparin.Type: ApplicationFiled: August 2, 2018Publication date: February 7, 2019Applicant: ExThera Medical CorporationInventors: KEITH MCCREA, ROBERT WARD, OLLE LARM, LARS ADOLFSSON